Latest Content

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.

Psychiatry is the medical specialty that wrestles with the included middle—requiring judgment, patience, and humility.

These are the 2 winners of the Hanusol Contest!

Explore the intersection of light and darkness through the lens of Hanukkah and the Winter Solstice, revealing insights on peace and human experience.

Explore the vital role of consultation liaison psychiatry in enhancing patient care and emotional well-being in complex medical conditions in our January 2026 theme!

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Psychiatry explores the complex interplay between obesity and mental health, advocating for integrated care to enhance treatment outcomes and reduce stigma.

Read part 1 of our lifestyle psychiatry special report, all in one place!

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.